Efficacy and safety of creatine supplementation in juvenile dermatomyositis: A randomized, double-blind, placebo-controlled crossover trial

ABSTRACT Introduction: It has been suggested that creatine supplementation is safe and effective for treating idiopathic inflammatory myopathies, but no pediatric study has been conducted to date. The objective of this study was to examine the efficacy and safety of creatine supplementation in juven...

Full description

Saved in:
Bibliographic Details
Published in:Muscle & nerve 2016-01, Vol.53 (1), p.58-66
Main Authors: Solis, Marina Yazigi, Hayashi, Ana Paula, Artioli, Guilherme Giannini, Roschel, Hamilton, Sapienza, Marcelo Tatit, Otaduy, Maria Concepción, De Sã Pinto, Ana Lucia, Silva, Clovis Artur, Sallum, Adriana Maluf Elias, Pereira, Rosa Maria R., Gualano, Bruno
Format: Article
Language:English
Subjects:
Adolescent
Body Composition
Bone Density
Child
Creatine - therapeutic use
creatine supplementation
Cross-Over Studies
Cytokines - blood
Dermatomyositis - diet therapy
Dermatomyositis - pathology
Dietary Supplements
Double-Blind Method
Eating - physiology
Exercise
Female
Humans
juvenile dermatomyositis
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Male
muscle metabolism
Muscle, Skeletal - metabolism
phosphocreatine
Phosphocreatine - metabolism
physical function
Quality of Life
Sensitivity and Specificity
Surveys and Questionnaires
Visual Analog Scale
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Introduction: It has been suggested that creatine supplementation is safe and effective for treating idiopathic inflammatory myopathies, but no pediatric study has been conducted to date. The objective of this study was to examine the efficacy and safety of creatine supplementation in juvenile dermatomyositis (JDM) patients. Methods: In this study, JDM patients received placebo or creatine supplementation (0.1 g/kg/day) in a randomized, crossover, double‐blind design. Subjects were assessed at baseline and after 12 weeks. The primary outcome was muscle function. Secondary outcomes included body composition, aerobic conditioning, health‐related quality of life, and muscle phosphocreatine (PCr) content. Safety was assessed by laboratory parameters and kidney function measurements. Results: Creatine supplementation did not affect muscle function, intramuscular PCr content, or any other secondary outcome. Kidney function was not affected, and no side effects were reported. Conclusions: Twelve weeks of creatine supplementation in JDM patients were well‐tolerated and free of adverse effects, but treatment did not affect muscle function, intramuscular PCr, or any other parameter. Muscle Nerve 53: 58–66, 2016
ISSN:0148-639X
1097-4598
DOI:10.1002/mus.24681